市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | Aldeyra Therapeutics, Inc. | 混合的 | 看跌 |
AIStockmoo 评分
-0.3
| 分析师共识 | NA |
| 内部交易活动 | NA |
| 价格波动 | 0.5 |
| 技术平均移动指标 | -1.0 |
| 技术振荡指标 | -0.5 |
| 平均 | -0.33 |
|
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 3.13% |
| 机构持股比例 | 56.79% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Knoll Capital Management, Llc | 30 Jun 2026 | 5,475,516 |
| Kingdon Capital Management, L.L.C. | 30 Jun 2026 | 2,652,315 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合